Chinese herb reduces risk for recurrent colorectal adenoma, plus more top stories in gastroenterology

One of the top stories in gastroenterology last week was about a double-blind, randomized clinical trial that showed the Chinese herb Coptis chinensis reduced the risk for recurrent colorectal adenoma.

Also, the FDA recently accepted an investigational new drug application for ABX464 for treatment of patients with moderate to severe ulcerative colitis — another top story.

Berberine safe, effective in reducing risk for recurrent colorectal adenoma

Berberine, a supplement originally extracted from the Chinese herb Coptis chinensis, helped to reduce risk for recurrent colorectal adenoma, according to study results. Read more.

FDA accepts investigational NDA for ulcerative colitis therapy

The FDA accepted the investigational new drug application for ABX464 for the treatment of patients with moderate to severe ulcerative colitis, according to the drug’s manufacturer. Read more.

CRC surveillance may be unnecessary after polypectomy in some patients

Patients at low and intermediate risk for colorectal cancer may not require postpolypectomy surveillance, according to research published in Gut. Read more.

Abdominal pain differs between IBS subtypes

The presentation and characteristics of abdominal pain are not the same among the different subtypes of irritable bowel syndrome, according to study results. Read more.

Microscopic colitis may increase risk for incident inflammatory bowel disease

Patients with microscopic colitis were at increased risk for incident inflammatory bowel disease, according to study results. Read more.